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Francesca Patriarca,1 Hermann Einsele,2 Francesco Spina,3 Benedetto Bruno,4 Miriam Isola,5
Chiara Nozzoli,6 Andrea Nozza,7 Alessandra Sperotto,1 Fortunato Morabito,8
Gernot Stuhler,2 Moreno Festuccia,4 Alberto Bosi,6 Renato Fanin,1 Paolo Corradini9Allogeneic stem cell transplantation (allo-SCT) using reduced-intensity conditioning (RIC) is a feasible
procedure in selected patients with relapsed multiple myeloma (MM), but its efficacy remains a matter of
debate. The mortality and morbidity related to the procedure and the rather high relapse risk make the
use of allo-SCT controversial. In addition, the availability of novel antimyeloma treatments, such as bortezo-
mib and immunomodulatory agents, have made allo-SCT less appealing to clinicians. We investigated the role
of RIC allo-SCT in patients with MM who relapsed after autologous stem cell transplantation and were then
treated with a salvage therapy based on novel agents. This study was structured similarly to an intention-to-
treat analysis and included only those patients who underwent HLA typing immediately after the relapse.
Patients with a donor (donor group) and those without a suitable donor (no-donor group) were compared.
A total of 169 consecutive patients were evaluated retrospectively in a multicenter study. Of these, 75
patients found a donor and 68 (91%) underwent RIC allo-SCT, including 24 from an HLA-identical sibling
(35%) and 44 from an unrelated donor (65%). Seven patients with a donor did not undergo allo-SCT for pro-
gressive disease or concomitant severe comorbidities. The 2-year cumulative incidence of nonrelapse mor-
tality was 22% in the donor group and 1% in the no-donor group (P\.0001). The 2-year progression-free
survival (PFS) was 42% in the donor group and 18% in the no-donor group (P\.0001). The 2-year overall
survival (OS) was 54% in the donor group and 53% in the no-donor group (P 5 .329). In multivariate anal-
ysis, lack of a donor was a significant unfavorable factor for PFS, but not for OS. Lack of chemosensitivity
after salvage treatment and high-risk karyotype at diagnosis significantly shortened OS. In patients who
underwent allo-SCT, the development of chronic graft-versus-host disease had a significant protective ef-
fect on OS. This study provides evidence for a significant PFS benefit of salvage treatment with novel drugs
followed by RIC allo-SCT in patients with relapsed MM who have a suitable donor.
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The spectrum of treatment options for patients
with relapsed multiple myeloma (MM) has changed
dramatically over the past 10 years. The introduction
of thalidomide, its analog lenalidomide, and the pro-1Hematology, Department of Experimental Clinical
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apeutic arsenal of salvage treatments. A response rate
of 30%-60% and a median response duration of
6-12 months has been achieved [1-4]. Moreover, an
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novel agents compared with patients who were never
exposed to these agents [5]. However, the majority of
patients develop resistance over time and continue to
suffer recurrent relapses; thus, long-term disease
control or cure cannot be achieved.
Allogeneic stem cell transplantation (allo-SCT) is
a potentially curative option because of a tumor-free
graft and a postulated graft-versus-myeloma effect.
Compared with the other treatment modalities for
MM, allo-SCT induces the highest rate of clinical
complete responses and molecular responses [6,7].
However, despite improvements in supportive care
and patient selection, allo-SCT with myeloablative
conditioning has a nonrelapse mortality (NRM) of
20%-44% due to organ toxicities, graft-versus-host
disease (GVHD), and infections [8,9]. Reduced-
intensity conditioning (RIC) transplantation regimens
were introduced in the late 1990s to reduce the toxic-
ity of the preparatory regimens and to maintain the
immunologic effect of donor lymphoid cells (ie,
graft-versus-tumor effect) [10]. Currently, the most
consolidated results of RIC allo-SCT have been re-
ported in patients with newly diagnosed MM with
an HLA-identical sibling donor after tumor burden
reduction with high-dose therapy followed by
autologous stem cell transplantation (auto-SCT). A
few randomized trials have compared this strategy
with auto-SCT alone [11-14], and 2 of those studies
suggested superior event-free survival and overall sur-
vival (OS) in patients who underwent allo-SCT
[12,13]. The use of RIC allo-SCT in relapsed patients
has been tested only in retrospective trials and in only
1 prospective phase II study limited to patients receiv-
ing transplants from unrelated donors [10,15-27]. The
largest study to date, from the European Group for
Blood and Marrow Transplantation [15], included
229 patients with a heterogeneous pretransplantation
disease status. The most common limitation was the
high rate of disease progression, particularly in pa-
tients with advanced disease and in heavily pretreated
patients; other important open questions were the in-
creased NRM in patients receiving transplants from
unrelated donors and the high morbidity due to
chronic GVHD in elderly recipients.
Salvage treatment with novel agents and RIC
allo-SCT are not alternative therapies per se. It can
be hypothesized that the use of a salvage treatment
incorporating novel agents followed by RIC allo-
SCT at the time of the first relapse after auto-SCT
can provide good disease control. To evaluate RIC
allo-SCT as a realistic salvage option in the clinical set-
ting of relapsed MM, we performed a retrospective
analysis in patients who relapsed after single or tandem
auto-SCT and were treated with novel agents. The
participating centers were 7 hematologic institutions
that in the last decade have independently adopteda policy of HLA-typing patients and their siblings
and/or starting an unrelated donor search soon after
failure of auto-SCT because of the intention to pro-
ceed to allo-SCT. Our study was structured similarly
to an intention-to-treat analysis; outcomes were com-
pared in patients in whom a sibling or unrelated donor
had been identified (donor group) and those without
a suitable donor (no-donor group). The objective of
the study was to examine whether having a donor
might be beneficial for the outcome of patients with
MM who relapsed after treatment with a salvage ther-
apy incorporating novel agents at the time of the first
relapse after auto-SCT.PATIENTS AND METHODS
Patients
Between 2002 and 2008, in the 7 participating
centers, a total of 619 patients with newly diagnosed
MM underwent single or tandem auto-SCT, 291 of
whom relapsed after autografting. Of these patients,
169 fullfilled the study criteria and were enrolled in
this retrospective study. The study design was
approved by the Institutional Review Boards of all
7 participating institutions. This study was structured
as follows. First, a synopsis of the study was sent to the
centers. After agreeing to join the study, a center
received a letter explaining how to collect the data
required on a specific patient form. Each center desig-
nated an investigator in charge of the study. Each
center reviewed all of the patients with MM who
relapsed after single or tandem auto-SCT between
2002 and 2008, including those patients who had
a clinical relapse requiring treatment, received a single
salvage treatment including new drugs (thalidomide or
lenalidomide or bortezomib), and underwent HLA
typing within 30 days after the relapse date with the
aim of identifying a sibling and/or unrelated donor
and performing an allo-SCT within 1 year after
relapse. The patient forms returned by the centers
were reviewed by a statistician and a senior hematolo-
gist, and, if necessary, specific queries were sent back to
the centers.
Disease response was evaluated through clinical
examination, blood chemistry tests, bone marrow
biopsy analysis, and imaging techniques (whole-skele-
ton X-ray and spinal magnetic resonance imaging, ac-
cording to each center’s policy). In cases of clinically
suspected extramedullary disease, appropriate imaging
techniques (magnetic resonance imaging, computed
tomography, or 18F-fluorodeoxyglucose positron
emission tomography) and/or needle aspiration or
biopsy were performed at the discretion of the attend-
ing physician. Karyotype at diagnosis was detected by
fluorescence in situ hybridization, if available, to assess
the following baseline abnormalities: t(14;14), deletion
Table 1. Characteristics of the Patients Who Underwent
Allo-SCT (n 5 68)
Time from diagnosis to allo-SCT, months,
median (range)
36 (9-168)
Donor, n (%)
HLA-matched sibling 24 (35)
Unrelated 44 (65)
HLA matching, n (%)
HLA-matched sibling 24 (44)
HLA-matched unrelated 24 (44)
HLA-mismatched unrelated 6 (12)
Missing 14
Source, n (%)
Bone marrow 11 (16)
Peripheral blood 57 (84)
Conditioning regimen, n (%)
Fludarabine, melphalan ± thiotepa 28 (41)
Fludarabine + 2 Gy TBI 24 (35)
Fludarabine + treosulfan 6 (9)
Fludarabine + cyclophosphamide 5 (7)
Busulfan-melphalan 2 (3)
Fludarabine + melphalan + 2 Gy TBI 2 (3)
Fludarabine + melphalan + 2 Gy TBI 1 (2)
ATG, n (%) 21 (31)
Acute GVHD, n (%)
Grade 0-I 40 (59)
Grade II-IV 28 (41)
Chronic GVHD, n (%)
Absent 32 (61)
Limited 6 (11)
Extensive 15 (28)
Not evaluable 15
DLI, n (%) 12 (18)
Antimyeloma treatment after allo-SCT, n (%) 36 (53)
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normalities identified a high-risk karyotype. Response
was evaluated according to the international uniform
response criteria for MM [28].
A search for a sibling donor was performed in all
169 enrolled patients, and another search for a suitable
unrelated donor was performed in 110 patients. The
search for an unrelated donor was not initiated in
59 patients because of the availability of an HLA-
matched sibling donor (n 5 28), patient refusal
(n 5 6), or medical decision (n 5 25). The attending
physicians decided to avoid the search for an unrelated
donor because of the following reasons: patient
age$60 years at relapse (n5 18), previous solid cancer
(n 5 3), or poor cardiac or lung function (n 5 4).
A total of 75 patients (44%) had a suitable donor,
and 94 (56%) did not. The latter patients were treated
according to the protocol of each center, with salvage
therapy continued as long as it was clinically required
(Figure 1).
Sixty-eight of the 75 patients with a donor (91%)
underwent allo-SCT (Table 1). Seven of these 75 pa-
tients (9%) did not receive the planned allo-SCT and
thus were excluded from the analysis of outcome re-
stricted to the allo-SCT patients, although they were
included in the donor versus no-donor analysis. Rea-
sons for not receiving allo-SCT were disease progres-
sion (n 5 4) and serious comorbidities (n 5 3).
Twenty-four of the patients undergoing allo-SCT
(35%) had an HLA-identical sibling donor, and 44
(65%) had an unrelated donor. For unrelated donors,
HLA typing for HLA-A, -B, -C, and -DRB1 loci was
required. Thirty unrelated donors had a known HLA
match; 24 of these donors were full 10/10 allele
HLA-matched, and the other 6 had a single antigen
mismatch in major histocompatibility complex class
I. Fifty-seven patients (84%) received peripheral
stem cells, and 11 (16%) received bone marrow. Pre-
parative regimens before allo-SCT were either RIC
or nonmyeloablative (NMA). These regimens in-
cluded fludarabine and melphalan with or without
thiotepa in 28 patients (41%), fludarabine plus 2 Gy169 multiple myeloma pts relapsed after auto-SCT between 2002-2008
all received a salvage treatment with novel agents
all underwent HLA typing and search for sibling or/and unrelated donor
75 pts found a donor
(DONOR GROUP)
68 pts underwent allo-SCT
24 sibling, 44 unrelated
(ALLO-GROUP)
94 pts continued treatment
with novel agents
94 pts did not find a donor
(NO-DONOR GROUP)
Figure 1. Flow chart of the study.total body irradiation (TBI) in 24 cases (35%), fludar-
abine and cyclophosphamide in 5 patients (7%),
fludarabine and treosulfan in 6 patients (9%), and
other combinations in 5 patients. GVHD prophylaxis
consisted of cyclosporine plus methotrexate in 44 pa-
tients and mycophenolate mofetil in 24 patients, with
the addition of antithymocyte globulin (ATG) in
21 of the 44 transplants from unrelated donors. Acute
and chronic GVHD were graded according to stan-
dard international criteria [29,30].Statistical Analysis
Data were collected in an XLS database and
imported into Stata/SE 9.0 for Windows (StataCorp,
College Station, TX) for statistical analysis. The
close-out date for analysis was December 2010. Two
analyses were performed: a so-called ‘‘donor versus
no-donor’’ analysis to compare the outcomes of
patients based on the availability of a donor, and an
analysis limited to patients undergoing allo-SCT to
assess the outcome RIC allo-SCT in patients with
MM. The starting points of our analyses were the
day of relapse after auto-SCT for the comparison of
the donor and no-donor groups and the day of allo-
SCT for the analysis restricted to the patients under-
going allo-SCT.
NRM was defined as death due to all causes not
related tomyeloma. The cumulative incidence method
Table 2. Clinical Characteristics of the Patients at Diagnosis
and at the Time of Auto-SCT
Donor Group
No-Donor
Group P
Number of patients 75 94
Age at auto-SCT, years,
median (range)
55 (34-68) 59 (31-73) <.001
M-component, n (%)
IgG 41 (55) 46 (50) .164
IgA 8 (11) 22 (23)
Bence-Jones protein 17 (22) 19 (20)
Other or nonsecretory 9 (12) 7 (7)
Stage, n (%)
I 6 (8) 5 (6)
II 8 (11) 18 (19) .274
III 61 (81) 71 (75)
Karyotype, n (%)
Standard risk 20 (60) 20 (57) .772
High risk 13 (40) 15 (43)
Missing 42 59
Diagnosis year, n (%)
#2000 21 (28) 16 (17) .188
2001-2003 21 (28) 40 (43)
$2004 33 (44) 38 (40)
Time from diagnosis to auto-SCT,
months, median (range)
8 (3-115) 8 (2-119) .274
Induction before auto-SCT, n (%)
Conventional agents 34 (72) 77 (82) .190
Novel agents 13 (28) 17 (18)
Missing 28 0
Tandem auto-SCT, n (%) 45 (60) 65 (69) .215
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GVHD, NRM, and relapse. Overall survival (OS)
was defined as the time (in months) from the afore-
mentioned starting points to either death or the last
observation. Progression-free survival (PFS) was
defined as the time from these starting points to
relapse, progression, death, or last observation. In
the allo-SCT group, salvage treatment consolidated
by allo-SCT was considered a unique treatment;
thus, relapse or progression was determined at the
time of the first evaluation after allo-SCT.
OS and PFS were described using the Kaplan-
Meier approach. The cumulative incidence method
was used to estimate relapse and NRM, accounting
for the presence of competing risks. Quantitative vari-
ables were tested for normal distribution using the
Kolmogorov-Smirnov test. Comparisons between
groups were performed using the t test or the Mann-
Whitney U test, depending on the Kolmogorov-
Smirnov test results. The c2 test was used to analyze
categorical values; when assumptions for c2 tests were
not verified, the Fisher exact test was used. Based on
the method of Fine and Gray (1999), competing-risk
regression was used to compare relapse and NRM in
the donor and no-donor groups. OS and PFS were an-
alyzed using Cox proportional hazard models, after the
proportional hazards assumption had been verified.
In univariate analysis, variables considered as pos-
sible prognostic factors were age at transplantation
(years), year of diagnosis (before 2000, 2000-2003,
2004 and after), interval between diagnosis and auto-
SCT (months), type of monoclonal gammopathy
(IgG, IgA, Bence-Jones, or nonsecretory), Durie and
Salmon stage (I, II, or III), karyotype at diagnosis
(high risk or standard risk), number of auto-SCTs (sin-
gle or double procedure), induction before auto-SCT
(conventional agent or novel drugs), extramedullary
myeloma at relapse (present or absent), interval
between auto-SCT and relapse (months), interval be-
tween relapse and start of salvage treatment (months),
type of salvage treatment (thalidomide-based,
bortezomib-based, or lenalidomide-based), duration
of salvage treatment (months), and response to salvage
treatment (responsive or unresponsive). In the patients
undergoing allo-SCT, time between diagnosis and
allo-SCT (months), disease status before SCT
(responsive or unresponsive), type of conditioning reg-
imen (RIC versus NMA), donor (sibling or unrelated),
HLA typing (HLA-matched related versus HLA-
matched unrelated versus HLA-mismatched unre-
lated), stem cell source (bone marrow or peripheral
blood), ATG (yes or no), acute GVHD (grade 0-I or
grade II-IV), chronic GVHD (absent or present),
and donor lymphocyte infusion (DLI; yes or no)
were considered as possible prognostic factors.
Acute and chronic GVHD were treated as time-
dependent variables. Multivariate stepwise analysesincluded all variables found to be significant at
P # .10 on univariate analysis. Retention in the step-
wise model required that the variable be significant
at P # .05 in multivariate analysis.RESULTS
Donor versus No-Donor Analysis: Comparison
of Patient Clinical Characteristics at Diagnosis
and at Relapse
The median patient age was significantly younger
in the donor group compared with the no-donor group
(55 versus 59 years; P # .001); however, the 2 groups
had similar main clinical characteristics at diagnosis
and at relapse (Tables 2 and 3). In fact, no significant
differences were detected between the 2 groups with
regard to type of M-component, MM stage at
diagnosis, high-risk karyotype at diagnosis, or year of
MM diagnosis, but the prevalence of extramedullary
manifestations was significantly higher in the donor
group (21% versus 9%; P 5 .042). The median time
between auto-SCT and relapse was 16 months in the
donor group and 17.5 months in the no-donor group
(P 5 .363), and the median interval between relapse
and the start of salvage treatment was #1 month in
both groups (P 5 .124). The type of salvage therapy
administered was not significantly different in the
2 groups, with thalidomide-based regimens in 52% of
the donor group and 39% of the no-donor group,
Table 3. Clinical Characteristics of the Patients at Relapse
Donor Group
No-Donor
Group P
Number of patients 75 94
Time from auto-SCT to relapse,
months, median (range)
16 (2-87) 17.5 (2-88) .363
Time from relapse to treatment,
months, median (range)
1 (0-23) 1 (0-51) .124
Clinical features at relapse, n (%)
Presence of extramedullary MM 10 (21) 8 (9) .042
Absence of extramedullary MM 37 (79) 82 (91)
Missing 28 4
Treatment of relapse, n (%)
Thalidomide-based 39 (52) 37 (39)
Bortezomib-based 25 (33) 31 (33)
Lenalidomide-based 7 (9) 17 (18) .194
Other drugs 4 (6) 9 (10)
Treatment duration, months,
median (range)
4 (1-52) 5 (1-55) .497
Response to relapse treatment, n (%)
Missing 15 9
CR + VGPR 20 (33) 25 (29) .09
PR 28 (47) 27 (32)
Resistance 7 (12) 16 (19)
Progression 5 (8) 17 (20)
Biol Blood Marrow Transplant 18:617-626, 2012 621Allogeneic Transplantation for Relapsed Multiple Myelomabortezomib-based regimens in 33%of the donor group
and 33% of the no-donor group, lenalidomide-based
regimens in 9% of the donor group and 18% of the
no-donor group, and other therapies in 6% of the
donor group and 10% of the no-donor group. The
median duration of salvage treatment was 4 months
in the donor group and 5 months in the no-donor
group (P5 .497). The quality of response after salvage
treatment did not differ significantly between the
2 groups (complete response [CR]1 very good partial
response [VGPR], 33% versus 29%; partial response
[PR], 47% versus 32%; resistance, 12% versus 19%;
progression, 8% versus 20%; P 5 .09).0
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Figure 2. Comparisons between donor and no-donor groups. (A) Incidenc
NRM (P 5 .0004).Survival Curves
The median follow-up after the beginning of
salvage treatment was 19 months (range, 1-97 months)
in all patients and 29 months (range, 6-88 months)
in surviving patients. At the last follow-up, 27 of
75 patients (36%) in the donor group and 24 of 94 pa-
tients (26%) in the no-donor group were alive and
maintained a clinical response (CR 1 PR). Overall,
111 of 169 patients (66%) progressed or relapsed after
therapy. For all patients, the median PFS was
12 months (range, 1-88 months), and the median OS
was 19 months (range, 1-97 months). The 2-year cu-
mulative incidence of relapse was 41% in the donor
group and 81% in the no-donor group (sub-hazard
ratio, 3.148; 95% confidence interval [CI], 2.098-
4.721; P \ .0001) (Figure 2A) The 2-year PFS was
42% in the donor group and 18% in the no-donor
group (hazard ratio [HR], 2.018; 95% CI, 1.392-
2.926; P \ .0001) (Figure 2B). The 2-year OS was
54% in the donor group and 53% in the no-donor
group (HR, 1.233; 95% CI, 0.809-1.879; P 5 .329)
(Figure 2C).
Novel agents associated with steroids or other
drugs were administered as second-line salvage treat-
ment in 23 of 25 patients (91%) of the donor group
and 44 of 52 patients (84%) of the no-donor group
and as third-line salvage treatment in 6 of 9 patients
(67%) of the donor group and 17 of 33 patients
(51%) of the no-donor group.
Prognostic factors that were significantly (P# .10)
associated with PFS in the univariate proportional haz-
ards model were unavailability of a donor (HR, 2.02;
95% CI, 1.39-2.92; P \ .001), duration of salvage
treatment (HR, 0.96; 95% CI, 0.94-0.99; P 5 .005),0.
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95% CI, 1.81-4.09; P \ .001). The variables that
showed a significant association with OS in the univar-
iate analysis were abnormal karyotype at diagnosis
(HR, 2.42; 95% CI, 1.17-4.99; P 5 .017), double
auto-SCT (HR, 1.49; 95% CI, 0.96-2.35; P 5 .079),
duration of salvage treatment (HR, 0.95; 95% CI,
0.91-0.98; P 5 .004), and unresponsiveness to salvage
treatment (HR, 3.68; 95% CI, 2.29-5.90; P\ .001).
Other clinical features of MM, such as patient age,
year of diagnosis, interval between diagnosis and
auto-SCT, type of monoclonal gammopathy, stage,
type of induction therapy, extramedullary relapse,
and interval between auto-SCT and relapse, were not
significant predictors for PFS and OS in univariate
analysis. In multivariate analysis, donor unavailability
was a significant unfavorable factor for PFS (HR,
2.86; 95% CI, 1.84-4.43), but not for OS (Table 4).
Lack of chemosensitivity after salvage treatment sig-
nificantly reduced both PFS and OS (HR, 2.37; 95%
CI, 1.57-3.58 and HR, 3.81; 95% CI, 1.76-8.24, re-
spectively). Moreover, high-risk karyotype at diagnosis
and previous treatment with double auto-SCT versus
single auto-SCT had a significant negative impact on
OS (HR, 2.37; 95% CI, 1.13-4.96 and HR 2.83; 95%
CI, 1.04-7.69, respectively). The only protective factor
identified was a longer duration of salvage treatment,
which was associated with better PFS (HR, 0.96;
95% CI, 0.93-0.98).Toxicity and NRM
A total of 91 of 169 patients (54%) died after treat-
ment. The causes of death were progressive disease in
73 patients (43%) and toxicity in 18 patients (11%).
Forty-one of 75 patients (55%) in the donor group
died, 24 from myeloma (32%) and 17 from toxicity
(23%). In the no-donor group, 50 of 94 patients
(53%) died, 49 (52%) due to disease and 1 (1%) due
to toxicity. The 2-year cumulative incidence of NRMTable 4. Multivariate Analysis of PFS and OS Data
Factor
PFS
HR 95% CI
Donor
Donor 1
No donor 2.860 1.844-4.435
Abnormal karyotype
Standard risk
High-risk
Auto-SCT
Single
Double
Duration of salvage treatment, months* 0.956 0.931-0.982
Response to salvage treatment
Responsive 1
Nonresponsive or progressive 2.373 1.574-3.577
*Modeled as a continuous variable.was 22% in the donor group and 1% in the no-
donor group (sub-hazard ratio, 0.049; 95% CI,
0.006-0.381; P 5 .0004) (Figure 2D).Outcome of Patients Undergoing Allo-SCT
A total of 68 of 75 patients (91%) with a donor
proceeded to RIC allo-SCT. The median time
between HLA typing and allo-SCT was 8 months
(range, 3-30 months); 52 of 68 patients (76%) under-
went transplantation within 12 months, and 16 of
68 (24%) did so within 24 months. At the last follow-
up, 19 of 68 patients (28%) were alive in stringent
CR (n5 7), CR (n5 8), or VGPR (n5 4), and another
8 patients (12%) were in PR; thus, 27 patients (40%)
maintained a clinical objective response. The median
observed PFS was 13 months, with an estimated 1-
year PFS of 64% and 2-year PFS of 38%. The median
observed OS was 35 months, with an estimated 1-year
OS of 73% and 2-year OS of 55% (Figure 3). Thirty-
six patients (48%) died, 19 (25%) due to disease pro-
gression and 17 (23%) due to transplantation-related
causes. This translates to a 1-year NRM of 18% and
2-year NRM of 22%. Grade II-IV acute GVHD
was seen in 28 evaluable patients (41%), and chronic
GVHD was seen in 21 (39%).
Thirty patients (44%) experienced relapse or pro-
gression after allo-SCT. Twelve patients received
a median of 1 DLI (range, 1-15) in association with 1
or more new drugs (thalidomide in 4 patients; bortezo-
mib in 8 patients; lenalidomide in 1 patient) because of
persistentMM (3 patients) or relapse (9 patients). Four
of these 12 patients (30%) had a long-term response
and were alive at a median follow-up of 30 months
(range, 13-46 months). Another 24 patients received
an antimyeloma drug after allo-SCT for maintenance
(3 patients) or treatment of relapse (21 patients).
Prognostic factors that were significantly (P# .10)
associated with PFS in the univariate proportional
hazards model were interval between diagnosis andOS
P HR 95% CI P
<.001
1
2.368 1.130-4.965 .022
1
2.835 1.045-7.690 .041
.001
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Figure 3. PFS (A) and OS (B) curves of patients who underwent
allo-SCT.
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progressive disease before transplantation (HR, 4.27;
95% CI, 1.01-16.56; P 5 .04), and development of
chronic GVHD (HR, 0.43; 95% CI, 0.18-1.04; P 5
.06). The final survival model showed no significant
prognostic factors for PFS. The variables with a signif-
icant association with OS in the univariate analysis
were interval between auto-SCT and relapse (HR,
1.012; 95%CI, 1.00-1.04; P5 .08), progressive disease
before transplantation (HR, 3.74; 95%CI, 0.81-17.28;
P 5 .09), T cell depletion with ATG (HR, 0.52; 95%
CI, 0.26-1.05; P 5 .07), and development of chronic
GVHD (HR, 0.32; 95% CI, 0.10-0.95; P 5 .04). In
multivariate analysis, development of chronic
GVHD maintained a protective effect on OS (HR,
0.11; 95% CI, 0.17-0.68; P 5 .02), whereas an in-
creased interval between auto-SCT and relapse was as-
sociated with poor OS (HR, 1.07; 95% CI, 1.01-1.13;
P 5 .02). In univariate analysis, no significant predic-
tors for NRM were identified among the main clinical
features of patients and transplants.DISCUSSION
In the last decade, RIC regimens have allowed the
use of allo-SCT in a greater number of patients withMM, even elderly and heavily pretreated patients, by
reducing NRM compared with myeloablative SCT
[10,15,16]. RIC allo-SCT has ensured sustained allo-
geneic engraftment in the majority of patients and
has demonstrated the possibility of inducing an antitu-
mor effect, even in patients with advanced disease [16].
However, as the clinical results of salvage treatment
with new drugs such as bortezomib and immunomod-
ulatory agents have become available [1-4], the initial
enthusiasm over RIC allo-SCT has been replaced by
some skepticism. For example, data from the registry
of the Gruppo Italiano Trapianto Midollo Osseo indi-
cates a 33% drop in the number of RIC allo-SCTs per-
formed between 2004 and 2009. Several randomized
trials of auto-SCT with or without NMA allo-SCT
fromHLA-identical sibling donors in newly diagnosed
patients have been conducted [11-14], and superior
event-free survival and OS in the allo-SCT arm have
been suggested in 2 of these studies [12,13]. The
incorporation of novel agents in the induction before
and after auto-SCT led to further improvement in
clinical results [31,32]; thus, this is considered the
standard approach for patients with newly diagnosed
MM, leaving upfront allo-SCT as a possible choice
for selected high-risk patients enrolled in prospective
clinical trials.
In patients with advanced relapse, no comparative
studies of RIC allo-SCT and salvage treatment at con-
ventional doses have been published, and retrospective
data are lacking. To our knowledge, the present study
is the first multicenter study comparing 2 different
treatment strategies for relapsed patients: allo-RIC
versus salvage treatment with new drugs. We retro-
spectively analyzed the data from 7 centers that be-
tween 2002 and 2008 adopted the same treatment
policy of offering RIC allo-SCT to all relapsed pa-
tients age\65 years old with an available sibling or
HLA-matched unrelated donor. To eliminate the pos-
sible bias due to progressive disease during the waiting
time for donor identification and/or transplant pro-
curement, a donor versus no-donor analysis of out-
come was performed. The only previous study with
a similar design was that of de Lavallade et al. [33];
however, their results were based on a single-center
analysis of only 32 patients.
In our study, the 2 groups had similar demographic
and clinical characteristics at diagnosis and at relapse.
The only significant difference was the younger
median age of the donor group, suggesting that youn-
ger patients have a greater likelihood of finding a suit-
able sibling donor and/or undergoing a search for an
unrelated donor. The interval between auto-SCT
and relapse was quite short in both groups (donor,
16 months; no-donor, 17.5 months) compared with
the PFS reported in most trials using auto-SCT pre-
ceded by conventional chemotherapy [34,35]. In
addition, the median time from detection of relapse
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necessitating treatment was only 1 month in both
groups. These observations could suggest a possible
selection of patients with high-risk relapse, for whom
the attending physician was more likely to decide to
search for a donor.
Our donor versus no-donor analysis showed that
the 2-year relapse rate was halved and the 2-year PFS
rate was significantly increased (by 20%) in the donor
group compared with the no-donor group. Moreover,
the lack of an HLA-matched suitable donor was
a significant unfavorable prognostic factor for PFS in
multivariate analysis. Unresponsiveness to salvage
treatment was the other factor that significantly short-
ened PFS.
In the multivariate analysis on OS data, we found
that having a donor had no significant impact on OS,
whereas high-risk cytogenetics and unresponsiveness
to salvage treatment were the main predictors of OS
for the entire population. With a longer follow-up,
the graft-versus-myeloma effect also might lead to
a better OS for the donor group, as was demonstrated
for PFS.
The statistical evidence of a poorer OS in patients
who relapsed after tandem auto-SCT compared with
those with single auto-SCT needs to be interpreted
with caution, given that cycles of high-dose therapy
were administered according to local protocols and
not on the basis of an uniform strategy. In addition,
the present study started only at the moment of relapse
after auto-SCT.
Although the fluorescence in situ hybridization
analysis was available for only 40% of the patients in
this study, detection of 13q deletion, 17p deletion, or
translocation (4;14) at diagnosis negatively influenced
OS irrespective of treatment. It is well known that pa-
tients with high-risk karyotypes relapse earlier after
single or tandem auto-SCT [36]. Some reported data
suggest that treatment with bortezomib and
immunomodulatory agents can overcome the negative
prognostic influence of a high-risk karyotype [37-40],
but these data need to be confirmed in prospective
trials on larger samples stratified on the basis of
specific cytogenetic abnormalities. The strong
correlation between high-risk karyotype and unfavor-
able outcome in our study could be explained in part
by the fact that the most common new drug incorpo-
rated in salvage therapies was thalidomide (52% in
the donor group, 39% in the no-donor group), which
has shown less-convincing efficacy data in high-risk
karyotype MM compared with lenalidomide and
bortezomib [40].
It is noteworthy that the quality of response after
salvage treatment at the time of first relapse was the
most important factor influencing OS (HR, 3.809).
Although not unexpected, this finding suggests that
the treatment of first relapse is critical to the subse-quent outcome. Therefore, no medical and economi-
cal efforts should be spared at this time, leaving
disease palliation to subsequent lines of treatment.
A minority of patients in our series had extrame-
dullary relapses, which were more frequent in the
donor group. However, extramedullary recurrences
after auto-SCT neither adversely affected the outcome
of the entire study population nor significantly wors-
ened the outcome of the donor group, suggesting the
efficacy of the novel agents used as salvage treatment,
as reported previously [41,42], and the possible
positive immunomodulating effect of allo-SCT [43].
The clinical results of allo-SCT in the present
study are comparable with previously published data.
We observed a 22% 1-year NRM, which is within
the 15%-37% range reported in previous studies
[15-26]. The NRM rate continued to increase in the
second year after transplantation, probably due to
chronic GVHD and infectious complications. The
NRM rate was similar in sibling and unrelated
transplants, as reported previously [24]; however, our
data did not confirm the increased NRM risk in trans-
plants from HLA-mismatched unrelated donors as re-
ported by Kr€oger et al. [24], although there were a few
such cases in our population. Nineteen of 68 patients
(28%) were in continuous complete clinical remission
at a median follow-up of 29 months, indicating that
allo-SCT at salvage can achieve long-term disease
control, confirming previously reported observations
[10,20,25,26].
We found no clear advantage or disadvantage of
using different conditioning regimens, including true
NMA regimens (eg, fludarabine plus 2-Gy TBI) and
RIC regimens with different types of alkylating agents.
T cell depletion with ATG, used in approximately
one-half of unrelated donor transplantations, showed
a protective effect on OS in univariate analysis, sug-
gesting a possible beneficial role, as reported by
Kr€oger et al. [23,24]. In fact, T cell depletion with
ATG did not lead to an increase in relapse rate after
allo-SCT, unlike alentuzumab [15], and allowed the
use of transplants from matched unrelated donors
with anNRM rate comparable to that seen with sibling
donors [23,24].
In this study, the immunomodulating effects of allo-
SCTwas demonstrated by the observation that chronic
GVHD was a significant predictor for prolonged PFS
and OS, in agreement with previous reports
[15,17,18,20,21]. In contrast, the use of allo-SCT late
in the course of disease and progressive MM before
allo-SCT were unfavorable prognostic factors. A few
studies suggested that a clinical response after allo-
SCT could be achieved in chemorefractory myelomas
as well [16], although chemosensitivity before allo-
SCT emerged as a significant factor for a long-term fa-
vorable outcome in most analyses [15,17,18,21].
Moreover, the administration of DLI in association
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30% of patients, which is within the 30%-60% range
reported in previous studies [16,18,27].
We acknowledge that our study has some limita-
tions. First, the availability of a donor was 44% in
the entire population and 54% in the group of patients
who underwent a search for both sibling and unrelated
donors, because 31 patients never looked for an unre-
lated donor due to either refusal or medical decision.
This 54% donor availability is slightly inferior to the
66% reported in a retrospective study of patients
with Hodgkin’s lymphoma with a similar donor versus
no-donor analysis [44]. However, our patients with
MM were much older than the patients in that study
(median age, 57 years versus 31 years) and were more
likely to have old or unfit sibling donors ineligible
for donation and thus never submitted to HLA typing.
Second, our patients were recruited over quite a long
period (between 2002 and 2008), during which diag-
nostic and treatment strategies changed. For example,
salvage treatment with thalidomide was more frequent
in the past, whereas nowadays bortezomib or lenalido-
mide are used more often. However, although this was
a retrospective study, selection bias was minimized by
the sharing of similar treatment policy and study
protocol by all participating institutions. Thus, we
believe that our original study design comparing out-
comes in patients with donors and patients treated
with the best available nontransplantation therapy
can help answer a relevant question: What is the role
of RIC transplantation in the management of young
patients with relapsed MM?
We confirmed that the NRM of RIC allo-SCT
from related and unrelated donors was lower than
previously reported rates. Moreover, we observed
that the association of a salvage treatment containing
novel agents consolidated by RIC allo-SCT resulted
in a significant prolongation of PFS in the donor group
compared with the no-donor group, but theOS advan-
tage was not significant. A longer follow-up likely is
needed to demonstrate a significant survival advantage
for the donor group. The protective effect of chronic
GVHD in patients undergoing allo-SCT and the clin-
ical response to DLI suggest a possible graft-versus-
myeloma effect, even in the relapse setting.
Our results indicate that allo-SCT can be an
option in young patients with relapsed MM and a suit-
able donor. However, as recently recommended by the
International Working Group Consensus statement
[45], new strategies should be explored in prospective
trials in selected groups of patients with the aim of
reducing NRM and relapse rates. Selection of patients
with chemosensitive disease, earlier planning of allo-
SCT, and incorporation of DLI and novel agents as
consolidation/maintenance after allo-SCT are some
suggested lines of investigation in prospective studies
to improve clinical results.ACKNOWLEDGMENTS
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